Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update on Chemotherapy-Induced Peripheral Neuropathy.

Comana Cioroiu1, Louis H Weimer2

  • 1Neurological Institute of New York, Columbia University Medical Center, 710 W168th Street, New York, NY, 10032, USA.

Current Neurology and Neuroscience Reports
|April 20, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Education Research: Integration of Trainee and Faculty Clinics at an Academic Medical Center: Improving Quality of Care and Education.

Neurology. Education·2026
Same author

Proprioceptive synaptic dysfunction is a key feature in mice and humans with spinal muscular atrophy.

Brain : a journal of neurology·2025
Same author

Biallelic Loss-of-Function Variants in <i>BICD1</i> Are Associated with Peripheral Neuropathy and Hearing Loss.

International journal of molecular sciences·2023
Same author

Lack of effect on ambulation of dalfampridine-ER (4-AP) treatment in adult SMA patients.

Neuromuscular disorders : NMD·2020
Same author

Neuromuscular disorders in pregnancy.

Handbook of clinical neurology·2020
Same author

Peripheral neuropathy symptoms in wild type transthyretin amyloidosis.

Journal of the peripheral nervous system : JPNS·2020
Same journal

The Noradrenergic Brain in Parkinson's Disease.

Current neurology and neuroscience reports·2026
Same journal

Mapping the Silent Onset of Parkinson's Disease: Monoamine Imaging in the Era of the Race for Preclinical Intervention.

Current neurology and neuroscience reports·2026
Same journal

Functional and Structural Brain Imaging Correlates of Treatment Response in Functional Movement Disorder.

Current neurology and neuroscience reports·2026
Same journal

Astrocytopathy in Wernicke Encephalopathy and Neuromyelitis Optica Spectrum Disorder. Pathogenic Differences With Occasional Clinical and Neuroimaging Overlap. A Review.

Current neurology and neuroscience reports·2026
Same journal

When is the Radiologically Isolated Syndrome already Multiple Sclerosis According to the 2024 McDonald Criteria?

Current neurology and neuroscience reports·2026
Same journal

Assessment and Management of Post-traumatic Headache.

Current neurology and neuroscience reports·2026
See all related articles

Chemotherapy-induced peripheral neuropathy (CIPN) is a significant side effect impacting patient quality of life. This review details current and emerging agents causing CIPN, emphasizing risk factors and clinical presentations.

Area of Science:

  • Neuroscience
  • Oncology
  • Pharmacology

Background:

  • Chemotherapy-induced peripheral neuropathy (CIPN) is a common and often dose-limiting toxicity associated with cancer treatment.
  • The clinical significance of CIPN and its impact on patient quality of life are increasingly recognized.
  • Ongoing research focuses on identifying risk factors for CIPN to enable better patient stratification.

Purpose of the Study:

  • To review the most important and recent chemotherapeutic agents implicated in CIPN.
  • To examine the mechanisms, risk factors, and clinical patterns of CIPN.
  • To discuss novel and prospective drugs with CIPN-like effects that may be less familiar to neurologists.

Main Methods:

  • Literature review of recent chemotherapeutic agents and their association with peripheral neuropathy.
Keywords:
EribulinIxabepiloneLenalidomideNivolumabPembrolizumabProteasome inhibitorsTaxanes

Related Experiment Videos

  • Analysis of established and emerging drug classes known to cause CIPN.
  • Examination of clinical presentations and potential risk factors for CIPN.

    • Main Results:

    • Newer agent classes, including immune checkpoint inhibitors, monoclonal antibodies, immunomodulatory agents, and proteasome inhibitors, are implicated in CIPN.
    • Established drug classes such as taxanes, platins, and vinca alkaloids continue to be associated with CIPN.
    • CIPN presents with diverse clinical patterns and is a critical factor in chemotherapy dose limitation.

    Conclusions:

    • Understanding the mechanisms and risk factors for CIPN is crucial for developing preventive and therapeutic strategies.
    • Continued surveillance of novel and established agents is necessary to manage CIPN effectively.
    • Future research should prioritize elucidating toxicity mechanisms and improving management of chemotherapy-induced peripheral neuropathy.